Clinical Trial Update: gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the gB/MF59 vaccine to prevent cytomegalovirus infection in healthy adolescent females has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• gB/MF59 CMV vaccine (glycoprotein B MF59-adjuvanted CMV vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Infections | Phase 2 | Status: COMPLETED